Literature DB >> 16002551

The cytoplasmic domain close to the transmembrane region of the glucagon-like peptide-1 receptor contains sequence elements that regulate agonist-dependent internalisation.

Patricia Vázquez1, Isabel Roncero, Enrique Blázquez, Elvira Alvarez.   

Abstract

In order to gain better insight into the molecular events involved in the signal transduction generated through glucagon-like peptide-1 (GLP-1) receptors, we tested the effect of deletions and point mutations within the cytoplasmic tail of this receptor with a view to establishing relationships between signal transduction desensitisation and receptor internalisation. Wild-type and truncated (deletion of the last 27 amino acids (GLPR 435R) and deletion of 44 amino acids (GLPR 418R)) GLP-1 receptors bound the agonist with similar affinity. Deletion of the last 27 amino acids decreased the internalisation rate by 78%, while deletion of 44 amino acids containing all the phosphorylation sites hitherto described in this receptor decreased the internalisation rate by only 47%. Binding of the ligand to both receptors stimulated adenylyl cyclase. In contrast, deletion of the region containing amino acids 419 to 435 (GLPR 419delta435) increased the internalisation rate by 268%, and the replacement of EVQ(408-410) by alanine (GLPR A(408-410)) increased this process to 296%. In both receptors, the efficacy in stimulating adenylate cyclase was decreased. All the receptors studied were internalised by coated pits, except for the receptor with a deletion of the last 44 amino acids, which also had a faster resensitisation rate. Our findings indicate that the neighbouring trans-membrane domain of the carboxyl-terminal tail of the GLP-1 receptor contains sequence elements that regulate agonist-dependent internalisation and transmembrane signalling.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002551     DOI: 10.1677/joe.1.06179

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

1.  Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor.

Authors:  Karen Coopman; Yan Huang; Neil Johnston; Sophie J Bradley; Graeme F Wilkinson; Gary B Willars
Journal:  J Pharmacol Exp Ther       Date:  2010-05-27       Impact factor: 4.030

Review 2.  Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes.

Authors:  Chris de Graaf; Dan Donnelly; Denise Wootten; Jesper Lau; Patrick M Sexton; Laurence J Miller; Jung-Mo Ahn; Jiayu Liao; Madeleine M Fletcher; Dehua Yang; Alastair J H Brown; Caihong Zhou; Jiejie Deng; Ming-Wei Wang
Journal:  Pharmacol Rev       Date:  2016-10       Impact factor: 25.468

3.  Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic beta cells.

Authors:  Shi-Ying Ding; Andongfac Nkobena; Catherine A Kraft; Michele L Markwardt; Mark A Rizzo
Journal:  J Biol Chem       Date:  2011-03-25       Impact factor: 5.157

Review 4.  Mechanisms of action of glucagon-like peptide 1 in the pancreas.

Authors:  Máire E Doyle; Josephine M Egan
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 5.  GLP-1: Molecular mechanisms and outcomes of a complex signaling system.

Authors:  Nicholas K Smith; Troy A Hackett; Aurelio Galli; Charles R Flynn
Journal:  Neurochem Int       Date:  2019-04-17       Impact factor: 3.921

Review 6.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

7.  Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation.

Authors:  Aiysha Thompson; Jeffrey W Stephens; Stephen C Bain; Venkateswarlu Kanamarlapudi
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.